Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EBT (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of EBT data on record, last reported at -$39.7 million in Q4 2023.

  • For Q4 2023, EBT fell 37.1% year-over-year to -$39.7 million; the TTM value through Dec 2023 reached -$169.2 million, down 211.83%, while the annual FY2025 figure was -$219.9 million, 31.3% down from the prior year.
  • EBT reached -$39.7 million in Q4 2023 per CGEM's latest filing, down from -$39.2 million in the prior quarter.
  • Across five years, EBT topped out at $240.1 million in Q2 2022 and bottomed at -$58.1 million in Q1 2023.
  • Average EBT over 4 years is -$9.1 million, with a median of -$28.2 million recorded in 2022.
  • The widest YoY moves for EBT: up 1560.76% in 2022, down 2387.53% in 2022.
  • A 4-year view of EBT shows it stood at -$29.1 million in 2020, then decreased by 17.57% to -$34.2 million in 2021, then increased by 15.38% to -$28.9 million in 2022, then plummeted by 37.1% to -$39.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for EBT were -$39.7 million in Q4 2023, -$39.2 million in Q3 2023, and -$32.2 million in Q2 2023.